Depression in women of reproductive age: Considerations in selecting safe, effective therapy

Postgraduate Medicine

Volumn 112, Issue 3, 2002, Pages 45-50

  Young, Stephen A ^a,b   Campbell, Nioaka ^b   Harper, Angela ^b  

^a Department of Clinical Psychiatry ^*  (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE MALEATE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AFFECTIVE NEUROSIS; BREAST FEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHOTHERAPY; PUERPERAL DEPRESSION; RISK BENEFIT ANALYSIS;

EID: 0036733330     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2002.09.1298     Document Type: Conference Paper

References (21)

1. Dubovsky SL, Buzan R. Mood disorders. In: Hales RE, Yudofsky SC, Talbott JA, eds. The American Psychiatric Press textbook of psychiatry. 3rd ed. Washington, DC: American Psychiatric Press, 1999:479-565
2. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276(4):293-9
3. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000; 157(6):924-30
4. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157(12): 1933-40
5. Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry 2000; 61(Suppl 12):9-16
6. The Royal Australian College of Obstetricians and Gynaecologists. Premenstrual syndrome (PMS). Available at: http://www.nevdgp.org.au/geninf /std_misc/PREMENSTRUAL_SYNDROME.htm. Accessed April 8, 2002
7. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332(23):1529-34
8. Yonkers KA, Halbreich U, Freeman E, et al. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996;32(1):41-6
9. Yonkers KA, Gullion C, Williams A, et al. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996;16(1):3-8
10. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry 1996;57(Suppl 8):56-60
11. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998;179(2): 444-52
12. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282(13):1264-9
13. Cohen LS. Update on reproductive safety of psychotropic medications. Curr Affective Illness 2001;20(5):5-11
14. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335(14):1010-5
15. Nulman I, Rover J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336(4): 258-62
16. Steiner M, Yonkers L. Depression in women. London: Martin Dunitz. 1998:33-5
17. Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999;104(1):e11. Available at: http: //www.pediatrics.org/cgi/content /full/104/1/e11. Accessed Apr 9, 2002
18. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry 1998;59(Suppl 2):41-52
19. Suri RA, Altshuler LL, Burt VK, et al. Managing psychiatric medications in the breast-feeding woman. Medscape Women's Health 1998; 3(1): 1-12
20. Stowe ZN, Calhoun K, Ramsey C, et al. Mood disorders during pregnancy and lactation: defining issues of exposure and treatment. CNS Spectrums 2001;6(2):150-66
21. Cohen LS. Update on reproductive safety of psychotropic medications. Part II. Curr Affective Illness 2001;20(6):5-12